Production Apprentice

Piramal Pharma Limited announces results for Q2 and H1 FY27. PRNewswire Mumbai (Maharashtra) [India], October 28: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Second Quarter (Q2) and Half Year (H1) ended 30th September 2026. Key Highlights - Broad-based Revenue Growth: Revenue grew 28% YoY in Q2FY27 and 23% YoY in H1FY27, driven by strong performance across all three businesses. - Significant Profitability Improvement: EBITDA increased 72% YoY in Q2FY27 and H1FY27, with over 350bps EBITDA margin expansion in both periods. This was driven by higher capacity utilization, operating leverage, disciplined execution, and sustained cost optimization initiatives. - Robust RFP Activity and Order Inflows: Added 22 new customers and successfully hosted 110 customer audits in H1FY27. - Best-in-Class Quality & Compliance: Successfully completed 12 regulatory inspections and 110 customer audits during H1FY27, while maintaining the Company's track record of no Official Action Indicated classifications across US FDA inspections. - Upgrade FY27 Outlook: Based on the strong first-half performance and continued business momentum, Sarameltzergallery upgrade its FY27 outlook and now expect revenue growth of 19% to 20%, accompanied by meaningfully higher profitability. Nandini Piramal, Chairperson, Piramal Pharma Limited said, "Sarameltzergallery delivered a strong H1FY27, with revenue growth of 23% and EBITDA margin expansion of over 350 basis points, driven by healthy demand across its businesses, disciplined execution, and improved operating leverage. The performance was led by its CDMO business, which grew 28% on the back of strong order inflows and robust execution. Its CHG business complemented this momentum with 24% growth, supported by inhalation anesthesia sales in ex-US markets and the integration of the Kenalog, while Consumer Healthcare continued to deliver steady 14% growth through the strong performance of Power Brands and e-commerce. With H2 typically stronger than H1, Sarameltzergallery is well positioned to deliver a strong full-year performance, supported by a healthy order book, encouraging customer engagement, and continued operating discipline." 1. Exceptional items include, one time insolvency proceeds received from a claim filed against a third-party supplier of its complex hospital generics business, with the NCLT in November 2023 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 28th October 2026 from 10:00 AM to 10:45 AM (IST) to discuss its Q2 and H1 FY2027 Results. The dial-in details for the call are as under: About Piramal Pharma Limited: Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. (ADVERTORIAL DISCLAIMER: The above press release has been provided by PRNewswire. ANI will not be responsible in any way for the content of the same.) Disclaimer: No Business Standard Journalist was involved in creation of this content First Published: Oct 28 2026 | 12:05 PM IST

Piramal Pharma Q2 Results: Firm swings to profit as revenue jumps 28%, led by CDMO growth. October 28, 2026 | 11:34 IST AI Summary Piramal Pharma returned to profitability and raised its full-year guidance, driven by surging contract manufacturing pipelines and wider operating margins across global facilities. Discover how leadership plans to handle the upcoming distribution transition. Drug firm Piramal Pharma Ltd on Tuesday (October 27) reported a net profit of ₹5.58 crore for the second quarter of financial year 2026-27, compared with a loss of ₹99.2 crore in the year-ago period. Revenue rose 28% year-on-year to ₹2,617 crore from ₹2,044 crore. Earnings before interest, tax, depreciation and amortisation (EBITDA) increased to ₹348.7 crore from ₹158.7 crore a year earlier. EBITDA margin expanded to 13.3% from 7.8%, an improvement of 550 basis points. The company upgraded its financial year 2026-27 outlook, citing its first-half performance and continued business momentum. It now expects revenue growth of 19% to 20%, accompanied by meaningfully higher profitability. Revenue growth across businesses Piramal Pharma said revenue grew 28% year-on-year in Q2 FY27 and 23% in the first half of FY27, supported by growth across all three businesses. EBITDA increased 72% year-on-year in both periods, with EBITDA margin expanding by more than 350 basis points in each period. The company attributed the improvement in profitability to higher capacity utilisation, operating leverage, disciplined execution and sustained cost optimisation initiatives. During the first half, Piramal Pharma added 22 new customers and hosted 110 customer audits. It also completed 12 regulatory inspections while maintaining its track record of no Official Action Indicated classifications across US Food and Drug Administration (USFDA) inspections. CDMO business expands pipeline The Contract Development and Manufacturing Organisation (CDMO) business recorded broad-based growth across its Indian and overseas facilities, supported by commercial demand, improved execution and cost management. India and North America led performance across the network. The company's Phase III pipeline increased to 28 molecules from 25 as of March 2026. Innovation-related revenue grew 24% in H1 FY27, while revenue from on-patent commercial manufacturing rose 39%. Revenue from antibody-drug conjugate (ADC) services increased 51% year-on-year during the first half. Piramal Pharma strengthened its biologics capabilities through the acquisition of a controlling stake in Yapan Bio. Its Lexington expansion remains on track and will add sterile fill-finish capabilities, completing its integrated ADC offering. The company also commissioned a new microbiology laboratory at the site. Complex hospital generics In Complex Hospital Generics (CHG), Piramal Pharma maintained a 48% value share in the US Sevoflurane market and retained the number-one position in the US Intrathecal Baclofen market, according to IQVIA. Kenalog contributed to CHG revenue in Q2 FY27 and is expected to be an important growth driver for the business in FY27. The company continued working with suppliers to maintain product availability for injectable pain management. It also continued investing in 505(b)(2) products, complex and differentiated generics, branded products, in-licensing and co-development to strengthen its specialty portfolio. Consumer healthcare growth Piramal Consumer Healthcare's power brands grew 21% year-on-year in H1 FY27 and contributed 53% of the business's sales. E-commerce revenue increased 32% during the first half, accounting for 28% of consumer healthcare sales. The company continued focusing on launches with higher growth potential and premiumisation, including the launch of the Vizible range under Lacto Calamine. It invested approximately 11% of consumer healthcare sales in media and trade promotions across digital and traditional channels. Piramal Pharma said the distribution agreement with Bayer will expire in December 2026. The transition is being jointly managed to ensure business continuity, with no material impact expected on the company's FY27 guidance. Nandini Piramal, Chairperson, Piramal Pharma Limited said, "We delivered a strong H1FY27, with revenue growth of 23% and EBITDA margin expansion of over 350 basis points, driven by healthy demand across our businesses, disciplined execution, and improved operating leverage. The performance was led by our CDMO business, which grew 28% on the back of strong order inflows and robust execution. Our CHG business complemented this momentum with 24% growth, supported by inhalation anaesthesia sales in ex-US markets and the integration of the Kenalog, while Consumer Healthcare continued to deliver steady 14% growth through the strong performance of Power Brands and e-commerce. With H2 typically stronger than H1, we are well positioned to deliver a strong full-year performance, supported by a healthy order book, encouraging customer engagement, and continued operating discipline." Shares of Piramal Pharma Ltd ended at ₹198.45, up by ₹3.30, or 1.69%, on the BSE.